Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2016 1
2017 1
2018 1
2019 1
2020 1
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Cognitive Dysfunctions and Assessments in Multiple Sclerosis.
Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L. Oreja-Guevara C, et al. Among authors: hernandez perez ma. Front Neurol. 2019 Jun 4;10:581. doi: 10.3389/fneur.2019.00581. eCollection 2019. Front Neurol. 2019. PMID: 31214113 Free PMC article. Review.
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, Wray S. Singer BA, et al. Among authors: hernandez perez ma. Mult Scler. 2023 Dec;29(14):1795-1807. doi: 10.1177/13524585231205708. Epub 2023 Oct 31. Mult Scler. 2023. PMID: 37905526 Free PMC article.
Successful desensitization to natalizumab using a 1-solution protocol.
Pérez-Rodríguez E, Hernández-Pérez MÁ, Martínez-Tadeo JA. Pérez-Rodríguez E, et al. Among authors: hernandez perez ma. Ann Allergy Asthma Immunol. 2017 Jan;118(1):113-114. doi: 10.1016/j.anai.2016.10.009. Epub 2016 Nov 15. Ann Allergy Asthma Immunol. 2017. PMID: 27864092 No abstract available.
Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale.
Sabin J, Salas E, Martín-Martínez J, Candeliere-Merlicco A, Barrero FJ, Alonso A, Sánchez-Menoyo JL, Borrega L, Rodríguez-Rodríguez M, Gómez-Gutiérrez M, Eichau S, Hernández-Pérez MÁ, Calles C, Fernández-Díaz E, Carmona O, Orvíz A, López-Real A, López-Muñoz P, Mendoza A, Agüera E, Maurino J, Ballesteros J. Sabin J, et al. Among authors: hernandez perez ma. Mult Scler J Exp Transl Clin. 2024 Apr 18;10(2):20552173241247680. doi: 10.1177/20552173241247680. eCollection 2024 Apr-Jun. Mult Scler J Exp Transl Clin. 2024. PMID: 38638273 Free PMC article.
Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing-Remitting Multiple Sclerosis: Quantifying the Patient's Perspective.
Meca-Lallana J, Maurino J, Hernández-Pérez MÁ, Sempere ÁP, Brieva L, García-Arcelay E, Terzaghi M, Saposnik G, Ballesteros J. Meca-Lallana J, et al. Among authors: hernandez perez ma. Neurol Ther. 2020 Jun;9(1):173-179. doi: 10.1007/s40120-020-00176-6. Epub 2020 Jan 18. Neurol Ther. 2020. PMID: 31955391 Free PMC article.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.